Regeneron has developed and validated a group of novel technology platforms to improve its ability to develop new product candidates.
VelociGene® and VelociMouse™ are designed to aid in the identification of specific genes of therapeutic interest for a particular disease or cell type and validate targets through high-throughput production of mammalian models. VelocImmune® is used to generate fully-human monoclonal antibodies to address clinically relevant targets of therapeutic interest. Traps are designed to trap specific extracellular signaling molecules (such as cytokines and growth factors) and may be used to block the activity of these molecules in certain disease settings.
- VelociGene
- VelociMouse
- VelocImmune
- Antibodies
- Traps
Read about Regeneron's protein production capabilities.
Highlights
Regeneron is working on discovering and validating potential clinical development candidates in the following therapeutic areas: